Overview#
TD Cowen has reaffirmed a Buy rating on Compass Pathways (NASDAQ:CMPS) with a price target of $29.00. The stock has seen a significant increase of 37% over the past week, currently trading near its 52-week high of $9.57. This surge reflects growing investor interest following recent regulatory advancements.
Positive Regulatory Developments#
The firm highlights the Commissioner’s National Priority Voucher (CNPV) as a significant positive step. This initiative, announced last Saturday, aims to speed up the development and accessibility of psychedelic-based therapies for neuropsychiatric disorders. TD Cowen anticipates that the approval for Compass Pathways’ ’360 product could happen as early as the fourth quarter of 2026, paving the way for a potential launch in the first quarter of 2027.
FDA Review Process#
The CNPV is expected to expedite the review timelines by the U.S. Food and Drug Administration (FDA), which oversees the safety and effectiveness of new drugs. The Drug Enforcement Administration (DEA) is also expected to review the safety data for the ’360 product alongside the FDA’s evaluation. This parallel review process could enhance the likelihood of a timely approval.
Recent Progress with COMP360#
In addition to these developments, Compass Pathways has made notable progress with its synthetic psilocybin treatment, COMP360, aimed at treating resistant depression. The FDA has granted a rolling New Drug Application (NDA) review for COMP360, which allows for quicker communication and a shorter review period of one to two months while still ensuring standard safety measures are met. Analysts have responded positively, with firms like Oppenheimer and Morgan Stanley expressing confidence in the product’s potential, indicating a growing optimism surrounding Compass Pathways’ innovative treatment strategies.